Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Advanced Renal Cell Carcinoma
Advertisement
Latest News
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.
Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC.
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Most patients in EMBARK recovered testosterone after treatment break, regardless of therapy or age.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.